I agree. With many years' experience in CVD research, clinical medicine, and clinical trials, I find the way in which the BTD has been overlooked or ignored by the market as extraordinary. Either investors have lost interest owing to past perceived failures in clinical studies with ABL, or are scared by new science and waiting for BP to take the lead. Is there any another possibility?

But I feel confident BP will be taking RVX very seriously behind the scenes.